Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.783
Filtrer
1.
Chem Biol Interact ; 399: 111131, 2024 Aug 25.
Article de Anglais | MEDLINE | ID: mdl-38964639

RÉSUMÉ

Dabrafenib is a BRAF inhibitor that has been demonstrated to be efficacious in the treatment of melanoma and non-small-cell lung cancer patients with BRAF V600E mutations. The objective of this study was to investigate the effects of 51 traditional Chinese medicines on the metabolism of dabrafenib and to further investigate the inhibitory effect of imperatorin. The quantification of dabrafenib and its metabolite hydroxy-dabrafenib was carried out using a sensitive, rapid, and accurate assay method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The results of in vitro experiments showed that 20 drugs inhibited the metabolism of dabrafenib by more than 80 %. In a further study of imperatorin on dabrafenib, the half-maximal inhibitory concentration (IC50) values of imperatorin on dabrafenib were 0.22 µM and 3.68 µM in rat liver microsomes (RLM) and human liver microsomes (HLM), respectively, while the inhibition mechanisms were non-competitive and mixed type inhibition, respectively. The results of in vivo experiments demonstrated that in the presence of imperatorin, the AUC(0-t), AUC(0-∞), Cmax, and Tmax of dabrafenib were increased by 2.38-, 2.26-, 1.05-, and 6.10-fold, respectively, while CLz/F was decreased by 67.9 %. In addition, Tmax of hydroxy-dabrafenib was increased by 1.4-fold. The results of the research showed that imperatorin had a consistent inhibitory effect on dabrafenib in vitro and in vivo. When the concurrent use of dabrafenib and imperatorin is unavoidable, clinicians should closely monitor for potential adverse events and make timely adjustments to the administered dosage.


Sujet(s)
Furocoumarines , Imidazoles , Microsomes du foie , Oximes , Rat Sprague-Dawley , Oximes/pharmacologie , Imidazoles/pharmacologie , Imidazoles/métabolisme , Animaux , Furocoumarines/pharmacologie , Furocoumarines/métabolisme , Microsomes du foie/métabolisme , Humains , Rats , Mâle , Spectrométrie de masse en tandem , Chromatographie en phase liquide à haute performance
2.
Molecules ; 29(12)2024 Jun 17.
Article de Anglais | MEDLINE | ID: mdl-38930940

RÉSUMÉ

Ammi majus L. (Apiaceae) is a medicinal plant with a well-documented history in phytotherapy. The aim of the present work was to isolate isopimpinellin (5,8-methoxypsoralen; IsoP) from the fruit of this plant and evaluate its biological activity against selected tumor cell lines. The methanol extract obtained with the use of an accelerated solvent extraction (ASE) method was the most suitable for the quantitative analysis of coumarins in the A. majus fruit matrix. The coumarin content was estimated by RP-HPLC/DAD, and the amount of IsoP was found to be 404.14 mg/100 g dry wt., constituting 24.56% of the total coumarin fraction (1.65 g/100 g). This, along with the presence of xanthotoxin (368.04 mg/100 g, 22.36%) and bergapten (253.05 mg/100 g, 15.38%), confirmed A. majus fruits as an excellent source of these compounds. IsoP was isolated (99.8% purity) by combined liquid chromatography/centrifugal partition chromatography (LC/CPC) and tested for the first time on its antiproliferative activity against human colorectal adenocarcinoma (HT29, SW620), osteosarcoma (Saos-2, HOS), and multiple myeloma (RPMI8226, U266) cell lines. MTT assay results (96 h incubation) demonstrated a dose- and cell line-dependent decrease in cell proliferation/viability, with the strongest effect of IsoP against the Saos-2 cell line (IC50; 42.59 µM), medium effect against U266, HT-29, and RPMI8226 (IC50 = 84.14, 95.53, and 105.0 µM, respectively), and very weak activity against invasive HOS (IC50; 321.6 µM) and SW620 (IC50; 711.30 µM) cells, as well as normal human skin fibroblasts (HSFs), with IC50; 410.7 µM. The mechanistic study on the Saos-2 cell line showed that IsoP was able to reduce DNA synthesis and trigger apoptosis via caspase-3 activation. In general, IsoP was found to have more potency towards cancerous cells (except for HOS and SW620) than against healthy cells. The Selective Index (SI) was determined, underlining the higher selectivity of IsoP towards cancer cells compared to healthy cells (SI = 9.62 against Saos-2). All these results suggest that IsoP might be a promising molecule in the chemo-prevention and treatment of primary osteosarcoma.


Sujet(s)
Ammi , Fruit , Furocoumarines , Extraits de plantes , Humains , Fruit/composition chimique , Lignée cellulaire tumorale , Furocoumarines/pharmacologie , Furocoumarines/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Ammi/composition chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Antinéoplasiques d'origine végétale/pharmacologie , Antinéoplasiques d'origine végétale/composition chimique , Apoptose/effets des médicaments et des substances chimiques , Chromatographie en phase liquide à haute performance , Survie cellulaire/effets des médicaments et des substances chimiques
3.
Chem Biol Interact ; 396: 111034, 2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38723799

RÉSUMÉ

This study aimed to explore the antioxidant and prooxidative activity of two natural furanocoumarin derivatives, Bergaptol (4-Hydroxy-7H-furo [3,2-g] [1]benzopyran-7-one, BER) and Xanthotoxol (9-Hydroxy-7H-furo [3,2-g] [1]benzopyran-7-one, XAN). The collected thermodynamic and kinetic data demonstrate that both compounds possess substantial antiradical activity against HO• and CCl3OO• radicals in physiological conditions. BER exhibited better antiradical activity in comparison to XAN, which can be attributed to the enhanced deprotonation caused by the positioning of the -OH group on the psoralen ring. In contrast to highly reactive radical species, newly formed radical species BER• and XAN• exhibited negligible reactivity towards the chosen constitutive elements of macromolecules (fatty acids, amino acids, nucleobases). Furthermore, in the presence of O2•─, the ability to regenerate newly formed radicals BER• and XAN• was observed. Conversely, in physiological conditions in the presence of Cu(II) ions, both compounds exhibit prooxidative activity. Nevertheless, the prooxidative activity of both compounds is less prominent than their antioxidant activity. Furthermore, it has been demonstrated that anionic species can engage in the creation of a chelate complex, which restricts the reduction of metal ions when reducing agents are present (O2•─ and Asc─). Moreover, studies have demonstrated that these chelating complexes can be coupled with other radical species, hence enhancing their ability to inactivate radicals. Both compounds exhibited substantial inhibitory effects against enzymes involved in the direct or indirect generation of ROS: Xanthine Oxidase (XOD), Lipoxygenase (LOX), Myeloperoxidase (MPO), NADPH oxidase (NOX).


Sujet(s)
Antioxydants , Furocoumarines , Furocoumarines/composition chimique , Furocoumarines/pharmacologie , Cinétique , Antioxydants/composition chimique , Antioxydants/pharmacologie , Théorie de la fonctionnelle de la densité , Oxydoréduction , Thermodynamique , Antienzymes/composition chimique , Antienzymes/pharmacologie , Lipoxygenase/métabolisme , Xanthine oxidase/métabolisme , Xanthine oxidase/antagonistes et inhibiteurs , Produits biologiques/composition chimique , Produits biologiques/pharmacologie , Piégeurs de radicaux libres/composition chimique , Piégeurs de radicaux libres/pharmacologie
4.
Biochemistry ; 63(10): 1241-1245, 2024 May 21.
Article de Anglais | MEDLINE | ID: mdl-38724483

RÉSUMÉ

Natural products are important sources of seed compounds for drug discovery. However, it has become difficult in recent years to discover new compounds with valuable pharmacological activities. On the other hand, among the vast number of natural products that have been isolated so far, a considerable number of compounds with specific biological activities are thought to be overlooked in screening that uses biological activity as an index. Therefore, it is conceivable that such overlooked useful compounds may be found by screening compound libraries that have been amassed previously through specific assays. Previously, NPD723, a member of the Natural Products Depository library comprised of a mixture of natural and non-natural products developed at RIKEN, and its metabolite H-006 were found to inhibit growth of various cancer cells at low nanomolar half-maximal inhibitory concentration. Subsequent analysis revealed that H-006 strongly inhibited human dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in the de novo pyrimidine biosynthetic pathway. Here, we elucidated the crystal structure of the DHODH-flavin mononucleotide-orotic acid-H-006 complex at 1.7 Å resolution to determine that furocoumavirin, the S-enantiomer of H-006, was the actual inhibitor. The overall mode of interaction of furocoumavirin with the inhibitor binding pocket was similar to that described for previously reported tight-binding inhibitors. However, the structural information together with kinetic characterizations of site-specific mutants identified key unique features that are considered to contribute to the sub-nanomolar inhibition of DHODH by furocoumavirin. Our finding identified new chemical features that could improve the design of human DHODH inhibitors.


Sujet(s)
Antiviraux , Dihydroorotate dehydrogenase , Humains , Antiviraux/pharmacologie , Antiviraux/composition chimique , Cristallographie aux rayons X , Dihydroorotate dehydrogenase/antagonistes et inhibiteurs , Dihydroorotate dehydrogenase/composition chimique , Antienzymes/pharmacologie , Antienzymes/composition chimique , Furocoumarines/pharmacologie , Furocoumarines/composition chimique , Modèles moléculaires
5.
Phytomedicine ; 130: 155760, 2024 Jul 25.
Article de Anglais | MEDLINE | ID: mdl-38797029

RÉSUMÉ

BACKGROUND: The Xin-yi-san herbal decoction (XYS) is commonly used to treat patients with allergic rhinitis in Taiwan. Theophylline is primarily oxidized with high affinity by human cytochrome P450 (CYP)1A2, and has a narrow therapeutic index. PURPOSE: This study aimed to investigate the inhibition of human CYP1A2-catalyzed theophylline oxidation (THO) by XYS and its adverse effects in patients. METHODS: Human CYPs were studied in recombinant enzyme systems. The influence of concurrent XYS usage in theophylline-treated patients was retrospectively analyzed. RESULTS: Among the major human hepatic and respiratory CYPs, XYS inhibitors preferentially inhibited CYP1A2 activity, which determined the elimination and side effects of theophylline. Among the herbal components of XYS decoction, Angelicae Dahuricae Radix contained potent THO inhibitors. Furanocoumarin imperatorin was abundant in XYS and Angelicae Dahuricae Radix decoctions, and non-competitively inhibited THO activity with Ki values of 77‒84 nM, higher than those (20‒52 nM) of fluvoxamine, which clinically interacted with theophylline. Compared with imperatorin, the intestinal bacterial metabolite xanthotoxol caused weaker THO inhibition. Consistent with the potency of the inhibitory effects, the docking analysis generated Gold fitness values in the order-fluvoxamine > imperatorin > xanthotoxol. During 2017‒2018, 2.6 % of 201,093 theophylline users consumed XYS. After inverse probability weighting, XYS users had a higher occurrence of undesired effects than non-XYS users; in particular, there was an approximately two-fold higher occurrence of headaches (odds ratio (OR), 2.14; 95 % confidence interval (CI), 1.99‒2.30; p < 0.001) and tachycardia (OR, 1.83; 95 % CI, 1.21‒2.77; p < 0.05). The incidence of irregular heartbeats increased (OR, 1.36; 95 % CI, 1.07‒1.72; p < 0.05) only in the theophylline users who took a high cumulative dose (≥ 24 g) of XYS. However, the mortality in theophylline users concurrently taking XYS was lower than that in non-XYS users (OR, 0.24; 95 % CI, 0.14‒0.40; p < 0.001). CONCLUSION: XYS contains human CYP1A2 inhibitors, and undesirable effects were observed in patients receiving both theophylline and XYS. Further human studies are essential to reduce mortality and to adjust the dosage of theophylline in XYS users.


Sujet(s)
Angelica , Inhibiteurs du cytochrome P-450 CYP1A2 , Cytochrome P-450 CYP1A2 , Médicaments issus de plantes chinoises , Furocoumarines , Théophylline , Théophylline/pharmacologie , Humains , Médicaments issus de plantes chinoises/pharmacologie , Cytochrome P-450 CYP1A2/métabolisme , Inhibiteurs du cytochrome P-450 CYP1A2/pharmacologie , Angelica/composition chimique , Furocoumarines/pharmacologie , Mâle , Interactions médicaments-plantes , Études rétrospectives , Femelle , Taïwan , Adulte d'âge moyen , Adulte , Oxydoréduction , Rhinite allergique/traitement médicamenteux , Rhinite allergique/induit chimiquement
6.
J Med Virol ; 96(5): e29669, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38773784

RÉSUMÉ

Chronic hepatitis B virus (HBV) infection remains a significant global health challenge due to its link to severe conditions like HBV-related cirrhosis and hepatocellular carcinoma (HCC). Although current treatments effectively reduce viral levels, they have limited impact on certain HBV elements, namely hepatitis B surface antigen (HBsAg) and covalently closed circular DNA (cccDNA). This highlights the urgent need for innovative pharmaceutical and biological interventions that can disrupt HBsAg production originating from cccDNA. In this study, we identified a natural furanocoumarin compound, Imperatorin, which markedly inhibited the expression of HBsAg from cccDNA, by screening a library of natural compounds derived from Chinese herbal medicines using ELISA assay and qRT-PCR. The pharmacodynamics study of Imperatorin was explored on HBV infected HepG2-NTCP/PHHs and HBV-infected humanized mouse model. Proteome analysis was performed on HBV infected HepG2-NTCP cells following Imperatorin treatment. Molecular docking and bio-layer interferometry (BLI) were used for finding the target of Imperatorin. Our findings demonstrated Imperatorin remarkably reduced the level of HBsAg, HBV RNAs, HBV DNA and transcriptional activity of cccDNA both in vitro and in vivo. Additionally, Imperatorin effectively restrained the actions of HBV promoters responsible for cccDNA transcription. Mechanistic study revealed that Imperatorin directly binds to ERK and subsequently interfering with the activation of CAMP response element-binding protein (CREB), a crucial transcriptional factor for HBV and has been demonstrated to bind to the PreS2/S and X promoter regions of HBV. Importantly, the absence of ERK could nullify the antiviral impact triggered by Imperatorin. Collectively, the natural compound Imperatorin may be an effective candidate agent for inhibiting HBsAg production and cccDNA transcription by impeding the activities of HBV promoters through ERK-CREB axis.


Sujet(s)
ADN circulaire , Furocoumarines , Antigènes de surface du virus de l'hépatite B , Virus de l'hépatite B , Transcription génétique , Furocoumarines/pharmacologie , Humains , Animaux , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/génétique , Antigènes de surface du virus de l'hépatite B/métabolisme , Antigènes de surface du virus de l'hépatite B/génétique , Cellules HepG2 , Souris , ADN circulaire/génétique , ADN circulaire/métabolisme , Transcription génétique/effets des médicaments et des substances chimiques , Antiviraux/pharmacologie , ADN viral , Simulation de docking moléculaire , Réplication virale/effets des médicaments et des substances chimiques , Protéine de liaison à l'élément de réponse à l'AMP cyclique/métabolisme , Hépatite B chronique/traitement médicamenteux , Hépatite B chronique/virologie , Modèles animaux de maladie humaine , Régions promotrices (génétique)
7.
Int J Mol Sci ; 25(10)2024 May 17.
Article de Anglais | MEDLINE | ID: mdl-38791498

RÉSUMÉ

The post-column reaction method enables the evaluation of the antiradical capacity of individual components in a mixture by separating the components using HPLC and measuring stable free radical (e.g., DPPH●) scavenging that occurs after the chromatography column. The equipment typically consists of two detectors. The first records signals of the analytes leaving the column. The second records radical scavenging by the analytes, which appears as a negative band. The recorded signals are found on two separate chromatograms, which must be combined to interpret the results. In this study, a single DAD detector was used behind the post-column reactor, enabling the simultaneous recording of the analyte bands and negative signals, indicating radical scavenging. The objective of this study was to evaluate the antiradical capacity of key compounds found in two herbal raw materials used in traditional Chinese medicine. Saposhnikovia divaricata roots contain phenolic acids, chromones, and furanocoumarins. Chlorogenic acid, rosmarinic acid, and imperatorin demonstrated strong radical scavenging, while prim-O-glucoslocimifugin showed a weaker response, both in standards and in root extracts. However, scavenging was not observed for cimifugin and 4'-O-ß-D-glucosyl-5-O-methylvisamminol. Astragalus mongholicus roots contain astragalosides I-IV (triterpene saponins). None of these showed DPPH● scavenging. Furthermore, additional signals were observed, indicating the presence of unidentified radical scavenging compounds.


Sujet(s)
Piégeurs de radicaux libres , Extraits de plantes , Plantes médicinales , Plantes médicinales/composition chimique , Extraits de plantes/composition chimique , Chromatographie en phase liquide à haute performance/méthodes , Piégeurs de radicaux libres/composition chimique , Apiaceae/composition chimique , Racines de plante/composition chimique , 4H-1-Benzopyran-4-ones/analyse , 4H-1-Benzopyran-4-ones/composition chimique , Furocoumarines/composition chimique , Furocoumarines/analyse
8.
Int J Mol Sci ; 25(8)2024 Apr 11.
Article de Anglais | MEDLINE | ID: mdl-38673809

RÉSUMÉ

Cnidium monnieri (L.) Cusson, a member of the Apiaceae family, is rich in coumarins, such as imperatorin and osthole. Cnidium monnieri fruit (CM) has a broad range of therapeutic potential that can be used in anti-bacterial, anti-cancer, and sexual dysfunction treatments. However, its efficacy in lowering blood pressure through vasodilation remains unknown. This study aimed to assess the potential therapeutic effect of CM 50% ethanol extract (CME) on hypertension and the mechanism of its vasorelaxant effect. CME (1-30 µg/mL) showed a concentration-dependent vasorelaxation on constricted aortic rings in Sprague Dawley rats induced by phenylephrine via an endothelium-independent mechanism. The vasorelaxant effect of CME was inhibited by blockers of voltage-dependent and Ca2+-activated K+ channels. Additionally, CME inhibited the vascular contraction induced by angiotensin II and CaCl2. The main active compounds of CM, i.e., imperatorin (3-300 µM) and osthole (1-100 µM), showed a concentration-dependent vasorelaxation effect, with half-maximal effective concentration values of 9.14 ± 0.06 and 5.98 ± 0.06 µM, respectively. Orally administered CME significantly reduced the blood pressure of spontaneously hypertensive rats. Our research shows that CME is a promising treatment option for hypertension. However, further studies are required to fully elucidate its therapeutic potential.


Sujet(s)
Antihypertenseurs , Pression sanguine , Cnidium , Éthanol , Fruit , Furocoumarines , Hypertension artérielle , Extraits de plantes , Rats de lignée SHR , Rat Sprague-Dawley , Vasodilatateurs , Animaux , Cnidium/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Pression sanguine/effets des médicaments et des substances chimiques , Rats , Fruit/composition chimique , Vasodilatateurs/pharmacologie , Mâle , Antihypertenseurs/pharmacologie , Éthanol/composition chimique , Furocoumarines/pharmacologie , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/physiopathologie , Vasodilatation/effets des médicaments et des substances chimiques , Coumarines/pharmacologie , Coumarines/composition chimique
9.
Virology ; 595: 110065, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38569227

RÉSUMÉ

Nucleot(s)ide analogues, the current antiviral treatments against chronic hepatitis B (CHB) infection, are non-curative due to their inability to eliminate covalently closed circular DNA (cccDNA) from the infected hepatocytes. Preclinical studies have shown that coumarin derivatives can effectively reduce the HBV DNA replication. We evaluated the antiviral efficacy of thirty new coumarin derivatives in cell culture models for studying HBV. Furanocoumarins Fc-20 and Fc-31 suppressed the levels of pre-genomic RNA as well as cccDNA, and reduced the secretion of virions, HBsAg and HBeAg. The antiviral efficacies of Fc-20 and Fc31 improved further when used in combination with the hepatitis B antiviral drug Entecavir. There was a marked reduction in the intracellular HBx level in the presence of these furanocoumarins due to proteasomal degradation resulting in the down-regulation of HBx-dependent viral genes. Importantly, both Fc-20 and Fc-31 were non-cytotoxic to cells even at high concentrations. Further, our molecular docking studies confirmed a moderate to high affinity interaction between furanocoumarins and viral HBx via residues Ala3, Arg26 and Lys140. These data suggest that furanocoumarins could be developed as a new therapeutic for CHB infection.


Sujet(s)
Antiviraux , ADN circulaire , Furocoumarines , Virus de l'hépatite B , Proteasome endopeptidase complex , Transactivateurs , Protéines virales régulatrices ou accessoires , Réplication virale , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/génétique , Virus de l'hépatite B/physiologie , Virus de l'hépatite B/métabolisme , Réplication virale/effets des médicaments et des substances chimiques , Humains , Transactivateurs/métabolisme , Transactivateurs/génétique , ADN circulaire/métabolisme , ADN circulaire/génétique , Protéines virales régulatrices ou accessoires/métabolisme , Protéines virales régulatrices ou accessoires/génétique , Furocoumarines/pharmacologie , Antiviraux/pharmacologie , Proteasome endopeptidase complex/métabolisme , ADN viral/métabolisme , ADN viral/génétique , Régulation négative/effets des médicaments et des substances chimiques , Transcription génétique/effets des médicaments et des substances chimiques , Protéolyse/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes viraux/effets des médicaments et des substances chimiques , Cellules HepG2
10.
Molecules ; 29(7)2024 Mar 22.
Article de Anglais | MEDLINE | ID: mdl-38611713

RÉSUMÉ

This study provides a comprehensive computational exploration of the inhibitory activity and metabolic pathways of 8-methoxypsoralen (8-MP), a furocoumarin derivative used for treating various skin disorders, on cytochrome P450 (P450). Employing quantum chemical DFT calculations, molecular docking, and molecular dynamics (MD) simulations analyses, the biotransformation mechanisms and the active site binding profile of 8-MP in CYP1B1 were investigated. Three plausible inactivation mechanisms were minutely scrutinized. Further analysis explored the formation of reactive metabolites in subsequent P450 metabolic processes, including covalent adduct formation through nucleophilic addition to the epoxide, 8-MP epoxide hydrolysis, and non-CYP-catalyzed epoxide ring opening. Special attention was paid to the catalytic effect of residue Phe268 on the mechanism-based inactivation (MBI) of P450 by 8-MP. Energetic profiles and facilitating conditions revealed a slight preference for the C4'=C5' epoxidation pathway, while recognizing a potential kinetic competition with the 8-OMe demethylation pathway due to comparable energy demands. The formation of covalent adducts via nucleophilic addition, particularly by phenylalanine, and the generation of potentially harmful reactive metabolites through autocatalyzed ring cleavage are likely to contribute significantly to P450 metabolism of 8-MP. Our findings highlight the key role of Phe268 in retaining 8-MP within the active site of CYP1B1, thereby facilitating initial oxygen addition transition states. This research offers crucial molecular-level insights that may guide the early stages of drug discovery and risk assessment related to the use of 8-MP.


Sujet(s)
Furocoumarines , Méthoxsalène , Méthoxsalène/pharmacologie , Simulation de docking moléculaire , Métabolisme secondaire , Furocoumarines/pharmacologie , Composés époxy
11.
Zhongguo Zhong Yao Za Zhi ; 49(5): 1369-1377, 2024 Mar.
Article de Chinois | MEDLINE | ID: mdl-38621985

RÉSUMÉ

A total of 11 active ingredients including psoralen, isopsoralen, bakuchiol, bavachalcone, bavachinin, corylin, coryfolin, isobavachalcone, neobavaisoflavone, bakuchalcone, and corylifol A from Psoraleae Fructus in the plasma samples of diabetic and normal rats were simultaneously determined by UHPLC-MS/MS. The pharmacokinetic parameters were calculated to elucidate the pharmacokinetic profiles of coumarins, flavonoids, and monoterpene phenols in normal and diabetic rats. The rat model of type 2 diabetes mellitus(T2DM) was induced by a high-sugar and high-fat diet combined with injection of 1% streptozotocin every two days. The plasma samples were collected at different time points after the rats were administrated with Psoraleae Fructus. The proteins in the plasma samples were precipitated by ethyl acetate, and the plasma concentrations of the 11 components of Psoraleae Fructus were determined by UHPLC-MS/MS. The pharmacokinetic parameters were calculated by DAS 3.0. The results showed that the pharmacokinetic beha-viors of 8 components including psoralen, isopsoralen, bakuchiol, and bavachinin from Psoraleae Fructus in both female and male mo-del rats were significantly different from those in normal rats. Among them, the coumarins including psoralen, isopsoralen, and corylin showed lowered levels in the blood of both female and male model rats. The flavonoids(bavachinin, corylifol A, and bakuchalcone) and the monoterpene phenol bakuchiol showed decreased levels in the female model rats but elevated levels in the male model rats. It is suggested that the dosage of Psoraleae Fructus should be reasonably adjusted for the patients of different genders at the time of clinical administration.


Sujet(s)
Diabète expérimental , Diabète de type 2 , Médicaments issus de plantes chinoises , Furocoumarines , Phénols , Psoralea , Humains , Rats , Femelle , Mâle , Animaux , Médicaments issus de plantes chinoises/pharmacocinétique , Spectrométrie de masse en tandem/méthodes , Diabète expérimental/traitement médicamenteux , Flavonoïdes/pharmacologie , Psoralène , Coumarines , Monoterpènes
12.
Phytochemistry ; 222: 114102, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38641144

RÉSUMÉ

Furanocoumarins (FCs) are widely distributed secondary metabolites found in higher plants, including Apiaceae, Rutaceae, Moraceae, and Fabaceae. They play a crucial role in the physiological functions of plants and are well-known for their diverse pharmacological activities. As a representative plant of the Apiaceae family, Angelica sinensis is highly valued for its medicinal properties and FCs are one of the main ingredients of A. sinensis. However, the biosynthetic mechanism of FCs in A. sinensis remains poorly understood. In this study, we successfully cloned and verified three types of enzymes using genome analysis and in vitro functional verification, which complete the biosynthesis of the FCs core skeleton in A. sinensis. It includes a p-coumaroyl CoA 2'-hydroxylase (AsC2'H) responsible for umbelliferone formation, two UbiA prenyltransferases (AsPT1 and AsPT2) that convert umbelliferone to demethylsuberosin (DMS) and osthenol, respectively, and two CYP736 subfamily cyclases (AsDC and AsOD) that catalyze the formation of FCs core skeleton. Interestingly, AsOD was demonstrated to be a bifunctional cyclase and could catalyze both DMS and osthenol, but had a higher affinity to osthenol. The characterization of these enzymes elucidates the molecular mechanism of FCs biosynthesis, providing new insights and technologies for understanding the diverse origins of FCs biosynthesis.


Sujet(s)
Angelica sinensis , Furocoumarines , Furocoumarines/composition chimique , Furocoumarines/métabolisme , Furocoumarines/biosynthèse , Angelica sinensis/composition chimique , Angelica sinensis/métabolisme , Structure moléculaire
13.
Int J Mol Sci ; 25(8)2024 Apr 11.
Article de Anglais | MEDLINE | ID: mdl-38673833

RÉSUMÉ

Though Isoimperatorin from Angelicae dahuricae is known to have antiviral, antidiabetic, anti-inflammatory and antitumor effects, its underlying antitumor mechanism remains elusive so far. Hence, the apoptotic mechanism of Isoimperatorin was explored in hepatocellular carcinomas (HCCs). In this study, Isoimperatorin inhibited the viability of Huh7 and Hep3B HCCs and increased the subG1 apoptotic portion and also abrogated the expression of pro-poly-ADP ribose polymerase (pro-PARP) and pro-caspase 3 in Huh7 and Hep3B cells. Also, Isoimperatorin abrogated the expression of cyclin D1, cyclin E1, CDK2, CDK4, CDK6 and increased p21 as G1 phase arrest-related proteins in Huh7 and Hep3B cells. Interestingly, Isoimperatorin reduced the expression and binding of c-Myc and Sirtuin 1 (SIRT1) by Immunoprecipitation (IP), with a binding score of 0.884 in Huh7 cells. Furthermore, Isoimperatorin suppressed the overexpression of c-Myc by the proteasome inhibitor MG132 and also disturbed cycloheximide-treated c-Myc stability in Huh7 cells. Overall, these findings support the novel evidence that the pivotal role of c-Myc and SIRT1 is critically involved in Isoimperatorin-induced apoptosis in HCCs as potent molecular targets in liver cancer therapy.


Sujet(s)
Apoptose , Carcinome hépatocellulaire , Furocoumarines , Tumeurs du foie , Protéines proto-oncogènes c-myc , Transduction du signal , Sirtuine-1 , Humains , Apoptose/effets des médicaments et des substances chimiques , Carcinome hépatocellulaire/métabolisme , Carcinome hépatocellulaire/anatomopathologie , Carcinome hépatocellulaire/traitement médicamenteux , Carcinome hépatocellulaire/génétique , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Tumeurs du foie/métabolisme , Tumeurs du foie/anatomopathologie , Tumeurs du foie/traitement médicamenteux , Tumeurs du foie/génétique , Protéines proto-oncogènes c-myc/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-myc/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Sirtuine-1/effets des médicaments et des substances chimiques , Sirtuine-1/métabolisme , Furocoumarines/pharmacologie
14.
Chem Res Toxicol ; 37(5): 804-813, 2024 May 20.
Article de Anglais | MEDLINE | ID: mdl-38646980

RÉSUMÉ

With the increasing use of oral contraceptives and estrogen replacement therapy, the incidence of estrogen-induced cholestasis (EC) has tended to rise. Psoralen (P) and isopsoralen (IP) are the major bioactive components in Psoraleae Fructus, and their estrogen-like activities have already been recognized. Recent studies have also reported that ERK1/2 plays a critical role in EC in mice. This study aimed to investigate whether P and IP induce EC and reveal specific mechanisms. It was found that P and IP increased the expression of esr1, cyp19a1b and the levels of E2 and VTG at 80 µM in zebrafish larvae. Exemestane (Exe), an aromatase antagonist, blocked estrogen-like activities of P and IP. At the same time, P and IP induced cholestatic hepatotoxicity in zebrafish larvae with increasing liver fluorescence areas and bile flow inhibition rates. Further mechanistic analysis revealed that P and IP significantly decreased the expression of bile acids (BAs) synthesis genes cyp7a1 and cyp8b1, BAs transport genes abcb11b and slc10a1, and BAs receptor genes nr1h4 and nr0b2a. In addition, P and IP caused EC by increasing the level of phosphorylation of ERK1/2. The ERK1/2 antagonists GDC0994 and Exe both showed significant rescue effects in terms of cholestatic liver injury. In conclusion, we comprehensively studied the specific mechanisms of P- and IP-induced EC and speculated that ERK1/2 may represent an important therapeutic target for EC induced by phytoestrogens.


Sujet(s)
Cholestase , Psoralène , Furocoumarines , Psoralea , Animaux , Produits biologiques/pharmacologie , Produits biologiques/composition chimique , Cholestase/induit chimiquement , Cholestase/métabolisme , Oestrogènes/métabolisme , Oestrogènes/pharmacologie , Psoralène/pharmacologie , Furocoumarines/pharmacologie , Furocoumarines/composition chimique , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Psoralea/composition chimique , Danio zébré
15.
Anticancer Drugs ; 35(6): 535-541, 2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38527238

RÉSUMÉ

Glioblastoma (GBM) is the most common primary malignant brain tumour and lacks therapeutic options with significant effects. The aberrant activation of STAT3 is a critical factor in glioma progression via activating multiple signalling pathways that promote glioma. Among them, the antiapoptotic gene Bcl-2 could be upregulated by p-STAT3, which is an important reason for the continuous proliferation of glioma. We previously reported that bergaptol, a natural furanocoumarin widely found in citrus products, exerts antineuroinflammatory effects by inhibiting the overactivation of STAT3. Here, we aimed to evaluate whether bergaptol could promote glioma apoptosis by inhibiting the STAT3/Bcl-2 pathway. This study found that bergaptol inhibited the proliferation and migration of GBM cell lines (U87 and A172) and promoted apoptosis in vitro. We also found that bergaptol significantly inhibited the STAT3/Bcl-2 pathway in GBM cells. U87 cells were implanted intracranially into nude mice to establish a glioma model, and glioma-bearing mice were treated with bergaptol (40 mg/kg). Bergaptol treatment significantly inhibited glioma growth and prolonged the glioma-bearing mice's survival time. In addition, bergaptol administration also significantly inhibited the STAT3/Bcl-2 pathway of tumour tissue in vivo. Overall, we found that bergaptol could effectively play an antiglioma role by inhibiting STAT3/Bcl-2 pathway, suggesting the potential efficacy of bergaptol in treating glioma.


Sujet(s)
Apoptose , Tumeurs du cerveau , Prolifération cellulaire , Gliome , Souris nude , Protéines proto-oncogènes c-bcl-2 , Facteur de transcription STAT-3 , Facteur de transcription STAT-3/métabolisme , Animaux , Humains , Prolifération cellulaire/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Souris , Protéines proto-oncogènes c-bcl-2/métabolisme , Tumeurs du cerveau/traitement médicamenteux , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/métabolisme , Gliome/traitement médicamenteux , Gliome/anatomopathologie , Gliome/métabolisme , Lignée cellulaire tumorale , Transduction du signal/effets des médicaments et des substances chimiques , Tests d'activité antitumorale sur modèle de xénogreffe , Furocoumarines/pharmacologie , Souris de lignée BALB C , Mouvement cellulaire/effets des médicaments et des substances chimiques , Flavanones
16.
Photochem Photobiol Sci ; 23(4): 693-709, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38457118

RÉSUMÉ

Psoralens are eponymous for PUVA (psoralen plus UV-A radiation) therapy, which inter alia can be used to treat various skin diseases. Based on the same underlying mechanism of action, the synthetic psoralen amotosalen (AMO) is utilized in the pathogen reduction technology of the INTERCEPT® Blood System to inactivate pathogens in plasma and platelet components. The photophysical behavior of AMO in the absence of DNA is remarkably similar to that of the recently studied psoralen 4'-aminomethyl-4,5',8-trimethylpsoralen (AMT). By means of steady-state and time-resolved spectroscopy, intercalation and photochemistry of AMO and synthetic DNA were studied. AMO intercalates with a higher affinity into A,T-only DNA (KD = 8.9 × 10-5 M) than into G,C-only DNA (KD = 6.9 × 10-4 M). AMO covalently photobinds to A,T-only DNA with a reaction quantum yield of ΦR = 0.11. Like AMT, it does not photoreact following intercalation into G,C-only DNA. Femto- and nanosecond transient absorption spectroscopy reveals the characteristic pattern of photobinding to A,T-only DNA. For AMO and G,C-only DNA, signatures of a photoinduced electron transfer are recorded.


Sujet(s)
Psoralène , Furocoumarines , Psoralène/pharmacologie , Psoralène/composition chimique , Furocoumarines/pharmacologie , Furocoumarines/composition chimique , ADN/composition chimique , Analyse spectrale
17.
J Ethnopharmacol ; 328: 117917, 2024 Jun 28.
Article de Anglais | MEDLINE | ID: mdl-38442807

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: The adverse effects of Fructus Psoraleae (FP), especially liver injury, have attracted wide attention in recent years. AIM OF THE STUDY: To establish a system to explore potential hepatotoxic targets and the chief culprit of liver injury based on clinical experience, network pharmacological method, molecular docking, and in vitro and in vivo experiments. MATERIALS AND METHODS: Clinical applications and adverse reactions to FP were obtained from public literatures. Components absorbed in the blood were selected as candidates to search for potential active targets (PATs) of FP. Subsequently, potential pharmacological core targets (PPCTs) were screened through the "drug targets-disease targets" network. Non-drug active targets (NPATs) were obtained by subtracting the PPCTs from the PATs. The potential hepatotoxic targets (PHTs) of FP were the intersection targets obtained from Venn analysis using NPATs, hepatotoxic targets, and adverse drug reaction (ADR) targets provided by the databases. Then, potential hepatotoxic components and targets were obtained using the "NPATS-component" network relationship. Molecular docking and in vitro and in vivo hepatotoxicity experiments were performed to verify the targets and related components. RESULTS: Overall, 234 NPATs were acquired from our analysis, and 6 targets were identified as PHTs. Results from molecular docking and in vitro and in vivo experiments showed that angelicin is the leading cause of liver injury in FP, and VKORC1 plays an important role. CONCLUSION: The results indicate that six targets, especially VKORC1, are associated with the PHTs of FP, and angelicin is the leading culprit involved in FP liver injury via inhibition of VKORC1.


Sujet(s)
Médicaments issus de plantes chinoises , Furocoumarines , Psoralea , Simulation de docking moléculaire , Foie , Furocoumarines/effets indésirables , Extraits de plantes/pharmacologie , Médicaments issus de plantes chinoises/pharmacologie
18.
J Cancer Res Clin Oncol ; 150(3): 130, 2024 Mar 15.
Article de Anglais | MEDLINE | ID: mdl-38489072

RÉSUMÉ

Psoralen is a family of naturally occurring photoactive compounds found in plants that acquire potential cytotoxicity when activated by specific frequencies of electromagnetic waves. Psoralens penetrate the phospholipid cellular membranes and insert themselves between the pyrimidines of deoxyribonucleic acid (DNA). Psoralens are initially biologically inert and acquire photoreactivity when exposed to certain classes of electromagnetic radiation, such as ultraviolet light. Once activated, psoralens form mono- and di-adducts with DNA, leading to marked cell apoptosis. This apoptotic effect is more pronounced in tumor cells due to their high rate of cell division. Moreover, photoactivated psoralen can inhibit tyrosine kinase signaling and influence the immunogenic properties of cells. Thus, the cytotoxicity of photoactivated psoralen holds promising clinical applications from its immunogenic properties to potential anti-cancer treatments. This narrative review aims to provide an overview of the current understanding and research on psoralen and to explore its potential future pharmacotherapeutic benefits in specific diseases.


Sujet(s)
Psoralène , Furocoumarines , Humains , Psoralène/pharmacologie , Psoralène/usage thérapeutique , Furocoumarines/pharmacologie , Rayons ultraviolets , ADN
19.
Acta Pharm ; 74(1): 67-79, 2024 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-38554381

RÉSUMÉ

Although the anticancer activity of Dorstenia foetida was already observed, the chemical entity responsible for this activity remained unidentified. In this study, the cytotoxic activity of two furanocoumarin compounds, i.e., 5-methoxy--3-(3-methyl-2,3-dihydroxybutyl)-psoralen (1) and 5-methoxy-3-(3-methyl-2,3-dihydroxybutyl)-psoralen diacetate (2) isolated from ethyl acetate fraction of D. foetida (whole plant) was investigated in several cancer cell lines including HN22, MDA-MB-231, HCT116, and HT29. The results revealed that compound 2 exhibited cytotoxic activity, particularly against colorectal cancer cell lines HCT116 and HT29. The interplay between compound 2 and irinotecan (Iri) showed synergism against HCT116, which was analyzed by CompuSyn software. The simulation revealed that, at the molar ratio of Iri:2 of 1:40, the concentration predicted to achieve a 90 % inhibitory effect when used in the combination would be ~28- and ~4-fold lower than the concentration of compound 2 and Iri, resp., when used individually. Finally, the percentage of apoptotic cells in the HCT116 line treated with the combination was markedly higher than in the cells treated with the individual agent (60 % apoptotic cells for the combination compared to 17 and 45 % for Iri and compound 2 monotherapy, resp). In conclusion, our results identified compound 2 as a plant-derived compound exhibiting anticancer properties that can act synergistically with Iri and warranted further research to assess the potential of this synergism for colorectal cancer treatment.


Sujet(s)
Antinéoplasiques , Tumeurs colorectales , Furocoumarines , Moraceae , Humains , Irinotécan , Furocoumarines/pharmacologie , Furocoumarines/composition chimique , Furocoumarines/usage thérapeutique , Lignée cellulaire tumorale , Moraceae/composition chimique , Tumeurs colorectales/traitement médicamenteux
20.
Biochem Biophys Res Commun ; 706: 149758, 2024 Apr 30.
Article de Anglais | MEDLINE | ID: mdl-38484571

RÉSUMÉ

Byakangelicin mostly obtained from the root of Angelica dahurica and has protective effect on liver injury and fibrosis. In addition, Byakangelicin, as a traditional medicine, is also used to treat colds, headache and toothache. Recent studies have shown that Byakangelicin exhibits anti-tumor function; however, the role of Byakangelicin in breast tumor progression and related mechanism has not yet been elucidated. Our study aims to investigate the role of Byakangelicin in breast tumor progression and the underlying mechanism. To measure the effect of Byakangelicin on JAK2/STAT3 signaling, a dual luciferase reporter assay and a Western blot assay were performed. CCK8, colony formation, apoptosis and cell invasion assays were used to examine the inhibitory potential of Byakangelicin on breast cancer cells. Additionally, SHP-1 was silenced by specific siRNA duplex and the function of SHP-1 on Byakangelicin-mediated inhibition of JAK2/STAT3 signaling was evaluated. Byakangelicin treatment significantly inhibited STAT3 transcriptional activity. In addition, Byakangelicin treatment blocked JAK2/STAT3 signaling in a dose-dependent manner. Byakangelicin-treated tumor cells showed a dramatically reduced proliferation, colony formation and invasion ability. Moreover, Byakangelicin remarkedly induced breast cancer cell apoptosis. Furthermore, Byakangelicin regulated the expression of SHP1.In conclusion, our current study indicated that Byakangelicin, a natural compound, inhibits SHP-1/JAK2/STAT3 signaling and thus blocks tumor growth and motility.


Sujet(s)
Tumeurs du sein , Furocoumarines , Transduction du signal , Humains , Femelle , Lignée cellulaire tumorale , Prolifération cellulaire , Apoptose , Tumeurs du sein/traitement médicamenteux , Facteur de transcription STAT-3/métabolisme , Kinase Janus-2/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE